CAR-T cell therapy for tough systemic lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with active SLE.
- Your lupus is still active after at least 3 months of standard treatments, including hydroxychloroquine, steroids, and at least one biologic.
- Your SLE activity score (SLEDAI-2K) is 7 or higher.
- You have positive ANA or anti-dsDNA antibodies in your blood.
- Your heart, kidneys, liver, and lungs are working well enough (tests will check this).
- You are not pregnant, and you agree to use reliable birth control for 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
This study tests a new type of treatment called CAR-T cells, which are specially engineered immune cells that may help control lupus by targeting the cells causing the disease. If you have active lupus despite standard treatments, this therapy might offer a new option to reduce symptoms and improve your condition.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.